Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data
This article was originally published in PharmAsia News
Executive Summary
In a new development following recent attention brought by a U.S. Senate Finance Committee report, the Saudi Arabia Food and Drug Authority has suspended the use of GlaxoSmithKline's Avandia (rosiglitazone) for six months while a review is under way
You may also be interested in...
In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.